

Seoul International Digestive Disease Symposium 2025

In Conjunction with the Annual Meeting of the Korean Society of Gastroenterology

April 19-20, 2025 | Swiss Grand Hotel Seoul, Korea



SIDDS 2025

Frontiers in Digestive Research and Practice

Name	Sangyoun Hwang
Affiliation	Dongnam Institute of Radiological & Medical Sciences (DIRAMS)
Country	South Korea
Major Field	Hepatocellular Carcinoma, Immunotherapy

Educational Background

Feb 2001 - Bachelor of Medicine (Pusan National University, School of Medicine)
Aug 2006 – Master of Internal Medicine (Pusan National University)
Feb 2015 – PhD of Internal Medicine (Pusan National University)

Professional Experience

2001-2002 Internship program, Pusan National University Hospital
2002-2006 Residency, Pusan National University Hospital
2008-2010 Clinical fellowship, Gastroenterology, Seoul National University Hospital,
2023-2023 Visiting Professor, Hepatology, University of Calgary, Canada

Main Scientific Publications

- (1) Hwang SY, Heo J et al. Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma. *Cancers*. 2024;16(4), 838.
- (2) Hwang SY, Lee SS et al. Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?. *Liver Cancer*. 2023 Nov;13:246-255.
- (3) Hwang SY et al. Multidisciplinary approaches to downstaging hepatocellular carcinoma: present and future. *J Liver Cancer* 2024;24:171-177.
- (4) Hwang SY, Kim JH et al. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study. *Eur J Cancer*. 2020 Nov;140:19-27.
- (5) Hwang SY, Yang KM et al. Emodin attenuates radioresistance induced by hypoxia in HepG2 cells via the enhancement of PARP1 cleavage and inhibition of JMJD2B. *Oncol Rep*. 2015 Apr;33(4):1691-8.